Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women
Radius Health, Inc. · Osteoporosis, Postmenopausal
Not applicable
Completed
22,054
2024-04
Industry sponsor intelligence
Radius Health, Inc.Clinical Pipeline.
Lead-sponsor view of Radius Health, Inc.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 11
- Recruiting
- 0
- Active
- 0
- Completed
- 11
- Results posted
- 9
- Avg enrollment
- 495
Pipeline overview
Programs by phase and activity.
Velocity
Radius Health, Inc. trials by start year
Study start year · indexed snapshot
Development
Trials by phase
10phase labels
Early Phase 10
Phase 13
Phase 22
Phase 35
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Abaloparatide → | 11 | 3 | 2 | 5 | 0 | 0 |
| Teriparatide → | 1 | 0 | 0 | 0 | 0 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Usability of Abaloparatide-solid Microstructured Transdermal System (sMTS) in Postmenopausal Women With Low Bone Mineral Density (BMD)
Radius Health, Inc. · Postmenopausal Osteoporosis
Phase 1
Completed
22
2023-11
Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)
Radius Health, Inc. · Osteoporosis · Osteoporosis, Age-Related
Phase 3
Completed
228
2023-04
Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis
Radius Health, Inc. · Postmenopausal Osteoporosis
Phase 3
Completed
511
2023-02
Study to Evaluate and Compare the PK Profiles of Abaloparatide-SC and Abaloparatide-sMTS in a Cohort of Healthy Men and Healthy Women.
Radius Health, Inc. · Healthy Volunteers
Phase 1
Completed
52
2022-01
Study to Evaluate and Compare the Bioequivalence of Two Abaloparatide-sMTS Treatments in Healthy Women.
Radius Health, Inc. · Osteoporosis
Phase 1
Completed
36
2022-01
Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption
Radius Health, Inc. · Osteoporosis, Postmenopausal · Osteoporosis
Phase 3
Completed
23
2021-10
Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis
Radius Health, Inc. · Postmenopausal Osteoporosis
Phase 3
Completed
1,139
2020-12
Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis
Radius Health, Inc. · Post Menopausal Osteoporosis
Phase 2
Completed
250
2020-06
Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis
Radius Health, Inc. · Osteoporosis
Phase 2
Completed
222
2017-10
Showing 10 of 11 studies
Search sponsor records
All Radius Health, Inc. studies.
This page groups studies where Radius Health, Inc. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
11 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT04974723Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal WomenApr 19, 2024NCT04366726Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Usability of Abaloparatide-solid Microstructured Transdermal System (sMTS) in Postmenopausal Women With Low Bone Mineral Density (BMD)Nov 22, 2023NCT03512262Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)Apr 7, 2023NCT04064411Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With OsteoporosisFeb 15, 2023NCT04663464Study to Evaluate and Compare the PK Profiles of Abaloparatide-SC and Abaloparatide-sMTS in a Cohort of Healthy Men and Healthy Women.Jan 6, 2022NCT04936984Study to Evaluate and Compare the Bioequivalence of Two Abaloparatide-sMTS Treatments in Healthy Women.Jan 6, 2022NCT03710889Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and ResorptionOct 15, 2021NCT01657162Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With OsteoporosisDec 11, 2020NCT01674621Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With OsteoporosisJun 16, 2020NCT00542425Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With OsteoporosisOct 30, 2017